Utsab Panta, MD
Interventional Cardiology · Elizabethtown, KYNPI 1689195729
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.8%), travel and lodging and grants — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2024 at $5,283 and has fallen 67.0% since, to $1,744 in 2025.
Across 140 payments — averaging $68.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$2K
- W. L. Gore & Associates, Inc.$2K
- Teleflex LLC$1K
- Amgen$257
- Medtronic$236
- plus $2K from 17 others
What the payments were for
- Grants$1,39815%
- Travel & lodging$3,33035%
- Food & beverage$4,49247%
- Education$3814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $2,058 |
| Boston Scientific | 14 | $1,881 |
| W. L. Gore & Associates, Inc. | 11 | $1,768 |
| Teleflex LLC | 11 | $1,440 |
| Amgen | 24 | $257 |
| Medtronic | 6 | $236 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $226 |
| AstraZeneca | 5 | $203 |
| Johnson & Johnson | 4 | $161 |
| Pfizer | 8 | $154 |
| Terumo Medical Corporation | 2 | $149 |
| Bayer | 2 | $147 |
| Asahi Intecc USA, Inc. | 2 | $142 |
| Merck | 7 | $121 |
| Shockwave Medical, Inc | 3 | $116 |
| Penumbra, Inc. | 1 | $107 |
| Novartis | 5 | $106 |
| Scpharmaceuticals Inc. | 1 | $90 |
| Abiomed | 3 | $74 |
| Chiesi USA, Inc. | 1 | $72 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Boehringer Ingelheim | 1 | $16 |
| Inari Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE CARDIOFORM Septal Occluder$1,639
- OPTIS$1,298
- GUIDELINER$1,061
- Diamondback Coronary$130
- AVVIGO Guidance System$128
- LOKELMA$125
- GlideWire$125
- Adempas$125
- TRAPLINER$124
- Indigo System$107
- PERIPHERAL VASCULAR$106
- MANTA$101
- XARELTO$100
How this compares
$9,600 in reported general payments places this provider in the 55th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 15 | $256 |
| Chlorthalidone | 16 | $186 |
| Carvedilol | 19 | $185 |
| Atorvastatin Calcium | 28 | $135 |
| Furosemide | 11 | $58 |
| Lisinopril | 17 | $41 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Elizabethtown
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
- Armaghan SoomroLexington$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.